Akebia Therapeutics, Inc. (AKBA)
Akebia Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Akebia Therapeutics, Inc. (AKBA) is a Biotechnology company based in US with a market capitalization of $348.7M. Revenue grew 47.5% year-over-year and the company generated $67.7M in free cash flow. This page tracks AKBA's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 181 employees · IPO Mar 20, 2014
Valuation
Valuation & price
$1.11as of May 15, 2026· -70.6% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
10.69
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$348.7M
Market cap
47.5%
Revenue growth (YoY)
83.3%
Gross margin
$67.7M
Free cash flow (USD)
$31.5M
Net debt
21.9%
Share dilution
0/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 7, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
Questions
Frequently asked questions
What is Akebia Therapeutics, Inc.'s market cap?
Akebia Therapeutics, Inc. (AKBA) has a market capitalization of $348.7M.
What is AKBA's P/E ratio?
A meaningful P/E ratio is not available for AKBA — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is AKBA's price-to-book (P/B) ratio?
AKBA trades at 10.69 times book value per share.
Are insiders buying AKBA stock?
SEC Form 4 filings show no open-market insider buys at Akebia Therapeutics, Inc. in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.